Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

R1 RCM Stock Surges Following Lucrative Acquisition Offer

Elaine Mendonca by Elaine Mendonca
February 26, 2024
in Breaking News
0
Healthcare cloud based
0
SHARES
5
VIEWS
Share on FacebookShare on Twitter

On February 26, 2024, R1 RCM is seeing a surge in its stock price following a lucrative acquisition offer of $13.75 per share. The company, known for its expertise in revenue cycle management, has garnered a “Moderate Buy” rating from analysts, who have set an average target price of $18.00.

In a recent strategic move, R1 RCM acquired Acclara for a hefty sum of $675 million in cash, along with a warrant allowing the purchase of up to 12.2 million shares of R1 stock at a strike price of $10.52. This acquisition further solidifies R1’s position in the competitive revenue cycle management industry, showcasing the company’s commitment to growth and expansion.

R1 RCM Inc. (RCM) Stock Surges 27.21% on February 26, 2024: Market Analysis

On February 26, 2024, R1 RCM Inc. (RCM) saw a significant increase in its stock performance. According to data from CNN Money, RCM is currently trading in the middle of its 52-week range and above its 200-day simple moving average, indicating a stable position in the market.

The price of RCM shares experienced a notable increase on this particular day, rising by $3.02 since the previous market close. This represents a substantial 27.21% increase in value, signaling positive momentum for the stock.

RCM opened at $14.05 on February 26th, which was $2.96 higher than its previous closing price. This strong opening suggests that investors were optimistic about the company’s prospects and were willing to pay a premium for RCM shares.

RCM Technologies, Inc. Reports Mixed Financial Results on February 26, 2024: Revenue Up, Net Income Down

On February 26, 2024, RCM Technologies, Inc. (RCM) reported its stock performances based on the financial data provided by CNN Money. The company’s total revenue for the past year was $1.81 billion, showing an increase of 22.5% compared to the previous year. However, the total revenue remained flat at $572.80 million for the third quarter.

In terms of net income, RCM reported a net loss of $63.30 million for the past year, which represents a significant decrease of 165.12% compared to the previous year. On the other hand, the net income for the third quarter was $1.30 million, showing an increase of 230.0% since the previous quarter.

Earnings per share (EPS) for RCM were reported at -$0.18 for the past year and $0.00 for the third quarter. This represents an increase of 90.34% in EPS since the previous year and a significant increase of 216.67% since the previous quarter.

Overall, the financial performance of RCM on February 26, 2024, showed mixed results. While the total revenue saw a significant increase compared to the previous year, the net income showed a significant decrease. However, the EPS for the company showed positive growth both year-over-year and quarter-over-quarter.

Investors and analysts will continue to monitor RCM’s financial performance in the coming quarters.

Tags: RCM
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Cleanest energy and ev

The Potential of Renewable Energy Integration: Harnessing Electric Vehicles as Grid Assets

Finance_ Charts for stock trading

Truist Securities Analyst Maintains Hold Rating on Main Street Capital with Increased Price Target

Biopharmaceutical Markets and money (1)

FDA Approval of Tevas SIMLANDI A GameChanger in Arthritis Treatment

Recommended

Gold Stock

Gold Nears Historic Peak as Market Anticipation Builds

2 months ago
Dentist

Advancements in Oral Healthcare: The Business Impact of Highly Trained Surgeons

2 years ago
Archer Aviation Stock

Archer Aviation Strengthens Market Position Through Strategic Patent Acquisition

4 months ago
SNDR stock news

Yousif Capital Management LLC Reduces Stake in Steven Madden, Ltd.: Implications for the Company’s Future Performance

3 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Graftech Shares Plunge on Bleak Quarterly Results

Potbelly Accelerates Northeast Growth with New Jersey Franchise Push

Conduent Faces Mounting Fallout from Major Data Breach Ahead of Earnings

Blue Ridge Bankshares Emerges from Regulatory Challenges with Return to Profitability

Navigating the Interest Rate Tightrope: Bank7’s Path Forward

Trending

Design Therapeutics Stock
Analysis

Design Therapeutics Approaches Key Clinical Milestones with Ample Funding

by Rodolfo Hanigan
February 7, 2026
0

Investor attention is turning to the upcoming catalysts for Design Therapeutics, a biotechnology firm advancing its GeneTAC...

Vigil Neuroscience Stock

Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy

February 7, 2026
Repay Holdings Stock

Repay Holdings: Annual Report to Test Strategic Refinancing Success

February 7, 2026
Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

Amazon’s $200 Billion Penalty, The Bad News Rally, and A Cloud Divorce

February 7, 2026
Graftech Stock

Graftech Shares Plunge on Bleak Quarterly Results

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Design Therapeutics Approaches Key Clinical Milestones with Ample Funding
  • Sanofi Completes Vigil Neuroscience Acquisition, Eyes Alzheimer’s Therapy
  • Repay Holdings: Annual Report to Test Strategic Refinancing Success

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com